New Project of World-leading Biopharmaceutical Enterprises Settled down in TEDA

On January 10, TEDA signed a cooperation agreement with Suzhou Ribo Life Science Co., Ltd. and Asymchem Labs. Ribo Life Science will cooperate with Tianjin Haihe Asymchem Biopharmaceutical Industry Innovation Investment Fund to invest in the construction of a kilogram-scale commercial production base for small nucleic acid crude drug in TEDA West.

In recent years, with the advantages of accurate targeting, remarkable efficacy and short development cycle, small nucleic acid drugs have become a new direction of global investment and a new focus for biopharmaceutical giants. It is estimated that its global market size will exceed $10 billion by 2025. Ribo Life Science is a main pioneer and leader in small nucleic acid technology and small nucleic acid pharmacy in China. Asymchem is a world’s leading CDMO company. With this partnership, Asymchem will provide the base with comprehensive services including design, construction, management and operation, and it will also highly cooperate with the R&D pipeline of Ribo Life Science to provide one-stop CDMO service mode. The mode will help innovative drug companies to focus more on the promotion of R&D pipeline and greatly accelerate the listing of new drugs and the development of enterprise.

With the mode, Haihe Asymchem Fund will invest in Ribo Life Science and deepen the cooperation in the future. The layout of small nucleic acid drugs will drive regional economic development and accelerate the development of small nucleic acid drugs in China. It will further promote the continuous gathering of more excellent innovative resources, form the collaboration of governments, capital and resources, and build a biomedical cooperation and innovation ecosystem with international competitiveness.